Chinese Hepatolgy ›› 2025, Vol. 30 ›› Issue (7): 972-974.

• Drug Induced Liver Injury • Previous Articles     Next Articles

Analysis of clinical characteristics in patients with statin-induced drug-induced liver injury

XU Yan1, PANG Xuan2   

  1. 1. Department of Pharmacy, Hai′an People′s Hospital, Hai′an 226600, China;
    2. Department of Cardiovascular Medicine, Hai′an People′s Hospital, Hai′an 226600, China
  • Received:2025-02-01 Online:2025-07-31 Published:2025-08-11

Abstract: Objective To analyze the clinical characteristics of patients with statin-induced drug-induced liver injury (SILI). Methods A total of 78 patients with SILI treated in our hospital from January 2022 to December 2024 were enrolled and divided into improved and unimproved groups based on clinical outcomes. The clinical data and prognostic factors were compared between the two groups. Results Among the 78 SILI patients, the statins used included atorvastatin, rosuvastatin, and simvastatin, with atorvastatin being the most frequently prescribed. The median time from drug initiation to liver injury onset was 90 (70, 122) days, and the median hospitalization duration was 10 (5, 18) days. Concurrent HBV infection was present in 13 cases (16.7%), and CYP450 enzyme gene variations were detected in 11 cases (14.4%). Among the 78 SILI patients, 53 showed improvement, while 25 did not. Significant differences (P<0.05) were observed between the improved and unimproved groups in age, statin dosage, time to liver injury onset, hospitalization duration, HBV coinfection, CYP450 gene variations, and levels of ALT, AST, and TBil. Age, statin dosage, HBV coinfection, and CYP450 gene variations were identified as independent risk factors affecting clinical prognosis (P<0.05). Conclusion Before prescribing statins, clinicians should thoroughly assess patients for pre-existing liver disease. During treatment, special attention should be paid to elderly patients and those receiving higher doses to minimize the risk of liver injury. Regular liver function monitoring, particularly after drug initiation, is essential to reduce adverse reactions.

Key words: Drug-induced liver injury, Statins, Atorvastatin